Press Coverage

Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer

13 July 2022

Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care, underscoring the key role of advanced imaging in slowing the rapid growth of esophageal cancer

Meta-analysis builds on recent data demonstrating that the use of Cellvizio is also associated with lower health services utilization and fewer overall endoscopy procedures

Latest News

Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums 

Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums 

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. 

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 

No results found.